Endogenous Erythropoietin as Part of the Cytokine Network in the Pathogenesis of Experimental Autoimmune Encephalomyelitis

Erythropoietin (EPO) is of great interest as a therapy for many of the central nervous system (CNS) diseases and its administration is protective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Endogenous EPO is induced by hypoxic/ischemic injury, but little is known about its expression in other CNS diseases. We report here that EPO expression in the spinal cord is induced in mouse models of chronic or relapsing-remitting EAE, and is prominently localized to motoneurons. We found a parallel increase of hypoxia-inducible transcription factor (HIF)-1α, but not HIF-2α, at the mRNA level, suggesting a possible role of non-hypoxic factors in EPO induction. EPO mRNA in the spinal cord was co-expressed with interferon (IFN)-γ and tumor necrosis factor (TNF), and these cytokines inhibited EPO production in vitro in both neuronal and glialcells. Given the known inhibitory effect of EPO on neuroinflammation, our study indicates that EPO should be viewed as part of the inflammatory/anti-inflammatory network in MS.

[1]  I. Kang,et al.  Lipopolysaccharide induces hypoxia-inducible factor-1 alpha mRNA expression and activation via NADPH oxidase and Sp1-dependent pathway in BV2 murine microglial cells , 2008, Neuroscience Letters.

[2]  G. Melillo,et al.  Synergystic induction of HIF-1α transcriptional activity by hypoxia and lipopolysaccharide in macrophages , 2008, Cell cycle.

[3]  T. Kietzmann,et al.  Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. , 2007, Molecular biology of the cell.

[4]  K. Nave,et al.  Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. , 2007, Brain : a journal of neurology.

[5]  E. Rankin,et al.  Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. , 2007, The Journal of clinical investigation.

[6]  T. Kietzmann,et al.  Reactive Oxygen Species Activate the HIF-1&agr; Promoter Via a Functional NF&kgr;B Site , 2007 .

[7]  W. Jelkmann.  Erythropoietin after a century of research: younger than ever , 2007, European journal of haematology.

[8]  R. Pedotti,et al.  Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis , 2006, Journal of Neuroimmunology.

[9]  P. Bigini,et al.  Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease , 2006, Experimental Neurology.

[10]  H. Ehrenreich,et al.  Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia , 2005, Anatomy and Embryology.

[11]  F. Tomasello,et al.  Erythropoietin and Erythropoietin Receptor Expression after Experimental Spinal Cord Injury Encourages Therapy by Exogenous Erythropoietin , 2005, Neurosurgery.

[12]  C. Stadelmann,et al.  Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis , 2004, Cell Death and Differentiation.

[13]  S. Elkabes,et al.  Beneficial effect of erythropoietin on experimental allergic encephalomyelitis , 2004, Annals of neurology.

[14]  P. Ghezzi,et al.  Erythropoietin as an antiapoptotic, tissue-protective cytokine , 2004, Cell Death and Differentiation.

[15]  S. Vilaró,et al.  Erythropoietin protects the in vitro blood–brain barrier against VEGF‐induced permeability , 2003, The European journal of neuroscience.

[16]  R. Reynolds,et al.  Molecular Changes in Normal Appearing White Matter in Multiple Sclerosis are Characteristic of Neuroprotective Mechanisms Against Hypoxic Insult , 2003, Brain pathology.

[17]  P. Ghezzi,et al.  Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis , 2003, The Journal of experimental medicine.

[18]  U. Dirnagl,et al.  Hypoxia-Induced Stroke Tolerance in the Mouse Is Mediated by Erythropoietin , 2003, Stroke.

[19]  K. Jellinger,et al.  Preferential Loss of Myelin‐Associated Glycoprotein Reflects Hypoxia‐Like White Matter Damage in Stroke and Inflammatory Brain Diseases , 2003, Journal of neuropathology and experimental neurology.

[20]  E. Oldfield,et al.  Vascular Endothelial Growth Factor Is Expressed in Multiple Sclerosis Plaques and Can Induce Inflammatory Lesions in Experimental Allergic Encephalomyelitis Rats , 2002, Journal of neuropathology and experimental neurology.

[21]  S. Frede,et al.  Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. , 2002, Blood.

[22]  S. Masuda,et al.  Pleiotropic functions and tissue-specific expression of erythropoietin. , 2001, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[23]  G. Semenza.  HIF-1 and mechanisms of hypoxia sensing. , 2001, Current opinion in cell biology.

[24]  R. Pedotti,et al.  An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide , 2001, Nature Immunology.

[25]  W. Brück,et al.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain , 2001, Acta Neuropathologica.

[26]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Mackenzie,et al.  A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  L. Overbergh,et al.  Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. , 1999, Cytokine.

[29]  S. Khoury,et al.  Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. , 1998, Journal of immunology.

[30]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Semenza,et al.  Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[32]  C. Noguchi,et al.  Regulated Human Erythropoietin Receptor Expression in Mouse Brain* , 1997, The Journal of Biological Chemistry.

[33]  G. Semenza,et al.  In vivo expression of mRNAs encoding hypoxia-inducible factor 1. , 1996, Biochemical and biophysical research communications.

[34]  M. Gassmann,et al.  Erythropoietin Gene Expression in Human, Monkey and Murine Brain , 1996, The European journal of neuroscience.

[35]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[36]  K. Mohler,et al.  Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. , 1992, Journal of immunology.

[37]  M. Sporn,et al.  Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. , 1992, International immunology.

[38]  P. Bigini,et al.  Immunohistochemical localization of TNFalpha and its receptors in the rodent central nervous system. , 2004, Methods in Molecular Medicine.

[39]  W. Jelkmann,et al.  Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. , 1992, Life sciences.